系统性自身免疫性风湿病患者 COVID-19 后的免疫学和临床后遗症-猫眼课题宝

系统性自身免疫性风湿病患者 COVID-19 后的免疫学和临床后遗症

批准号：

10583192

负责人：

Jeffrey Andrew Sparks

金额：

$78.25万

依托单位：

BRIGHAM AND WOMEN'S HOSPITAL

依托单位国家：

美国

项目类别：

财政年份：

2023

资助国家：

美国

项目状态：

未结题

起止时间：

2023-02-01 至 2028-01-31

来源：

https://reporter.nih.gov/project-details/10583192

关键词：

2019-nCoV Acute Affect American Antibodies Antibody Response Autoantibodies Autoimmunity B-Lymphocytes Biophysics COVID-19 COVID-19 impact COVID-19 pandemic COVID-19 pathogenesis COVID-19 risk COVID-19 survivors Characteristics Chest Chest imaging Clinical Community Hospitals Complication Coronavirus Data Diagnostic Disease Disease Outbreaks Dose Effectiveness Etiology Evolution Fibrosis General Hospitals General Population High Resolution Computed Tomography Hospitals Humoral Immunities Image Immune Immune response Immunologics Immunomodulators Immunosuppressive Agents Infection Knowledge Lead Massachusetts Measures Medicine National Institute of Arthritis, and Musculoskeletal, and Skin Diseases Observational Study Outcome Patients Phenotype Post-Acute Sequelae of SARS-CoV-2 Infection Predisposition Principal Investigator Prospective cohort Pulmonary Fibrosis RNA vaccine Recommendation Research Respiratory Signs and Symptoms Retrospective cohort study Rheumatoid Arthritis Risk SARS-CoV-2 infection Sampling Source Symptoms System Systemic Lupus Erythematosus TNF gene Vaccinated Vaccination Vaccines Variant Viral Virus Diseases Virus Shedding Vulnerable Populations Woman Work autoimmune rheumatologic disease breakthrough infection cohort coronavirus disease fibrotic lung disease high risk inhibitor medical schools pandemic disease participant enrollment pathogen post-COVID-19 professor prospective prototype public health relevance respiratory response rheumatologist rituximab tertiary care therapy resistant vaccine immunogenicity virology

项目摘要

项目成果

Jeffrey Andrew Sparks的其他基金

相似基金

相关文献

中文摘要

翻译

点击翻译按钮获取中文摘要

英文摘要

PROJECT SUMMARY The 5 million Americans living with systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), are at increased risk of poor COVID-19 outcomes. SARO treatment with immunomodulators may lead to blunted and dysregulated immune responses to vaccination and infection. SARDs are characterized by a predisposition to autoantibody formation and fibrosis. These factors may place SARDs at risk for poor short-term outcomes (e.g., breakthrough infection, prolonged viral shedding) and post-acute sequelae of COVID-19 (PASC), characterized by prolonged COVID-19 symptoms (>/=28 days). PASC is of high clinical and

期刊论文(0)

专著(0)

科研奖励(0)

会议论文